Self-management research of asthma and good drug use (SMARAGD study)

• Verfasst von: Kuipers, Esther [VerfasserIn]
• Verfasst von: Wensing, Michel [VerfasserIn]
• Titel: Self-management research of asthma and good drug use (SMARAGD study)
• Titelzusatz: a pilot trial
• Verf.angabe: Esther Kuipers, Michel Wensing, Peter de Smet, Martina Teichert
• E-Jahr: 2017
• Jahr: 09 June 2017
• Umfang: 9 S.
• Fussnoten: Gesehen am 09.11.2018
• Titel Quelle: Enthalten in: International journal of clinical pharmacy
• Ort Quelle: Dordrecht [u.a.] : Springer, 2011
• Jahr Quelle: 2017
• Band/Heft Quelle: 39(2017), 4, Seite 888-896
• ISSN Quelle: 2210-7711
• DOI: doi:10.1007/s11096-017-0495-6
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Adherence
• Sach-SW: Asthma
• Sach-SW: Inhalation corticosteroid maintenance therapy
• Sach-SW: Netherlands
• Sach-SW: Pharmacotherapy
• Sach-SW: Pharmacy practice research
• K10plus-PPN: 1582755132

Abstract

Background: Community pharmacists play an important role in supporting patients for optimal drug use. Objective To assess the effectiveness of monitoring in asthma patients with inhaled corticosteroids (ICS) on disease control. Setting: Asthma patients using ICS were invited from two intervention (IG) and two control pharmacies (CG). Method: Participating patients completed questionnaires at the study start and at 6-month follow-up, including the Control of Allergic Rhinitis and Asthma Test (CARAT) questionnaire. IG patients completed the CARAT questionnaire every 2 weeks and received counselling on disease management, ICS adherence, and inhalation technique when scores were suboptimal, deteriorating, or absent. For Turbuhaler users, additional electronic monitoring (EMI) was available, with daily alerts for ICS intake. Main outcome measure: As the primary outcome, CARAT scores at follow-up were compared between IG and CG using linear regression. As secondary outcome, refill adherence was compared using logistic regression. Results: From March to July 2015, we enrolled 39 IG and 41 CG patients. At follow-up, CARAT scores did not differ between IG and CG (−0.19; 95% confidence interval [CI], −2.57 to 2.20), neither did patient numbers with ICS adherence >80% (0.82; 95% CI, 0.28-2.37). Among EMI users, CARAT scores did not differ, but ICS adherence >80% showed a 4.52-fold increase (95% CI, 1.56-13.1) compared with EMI nonusers. Conclusion: Among community-dwelling asthma patients, pharmacist monitoring did not affect CARAT scores, but EMI use showed improved ICS refill adherence.